" class="no-js "lang="en-US"> Modus Therapeutics Archives - Medtech Alert
Thursday, March 28, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Modus Therapeutics Presented New Data on Anemia Treatment

Modus Therapeutics, a company developing innovative treatments for patients with major unmet medical needs, announces […]

Modus Therapeutics Announces Positive Topline Data from its Phase 1b LPS Provocation Study Evaluating the Potential of Sevuparin for Treatment of Sepsis

Modus Therapeutics, a company developing innovative treatments for patients with major unmet medical needs, announces […]

Modus Therapeutics Submits Patent Application for Sevuparin in Kidney Disease

Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more